The review came out of Quito, not Boston or Bethesda. That is the first detail worth noticing. A four-author team at the Universidad Técnica Particular de Loja pulled the preclinical record on ivermectin and cancer into one place last September, published it in Pharmaceuticals, and what surfaces is the answer the post-COVID consensus prepared no one for: a coherent and reproducible anticancer biology across ten tumor types, working through the same signaling pathways oncology spends billions trying to drug. The review is also honest that the human evidence to match it does not exist. That gap is the entire story.

The fingerprints repeat with unsettling consistency across the tumor lines the authors surveyed, including colorectal, ovarian, pancreatic, lung, prostate, esophageal squamous-cell, hepatocellular, melanoma, bladder, and the triple-negative breast subtype that has resisted almost everything else: mitochondrial collapse, oxidative stress, induced apoptosis, and modulation of Wnt/β-catenin, PI3K/Akt/mTOR, STAT3, NF-κB, and PAK1. In murine models, the drug reduces tumor volume by more than fifty percent at doses below the maximum tolerated in humans. The biology, in other words, is not a curiosity. It is a stack of mechanistic findings the field would normally regard as worth a Phase II.

The load-bearing problem the review treats honestly, and the laugh-track did not, is the pharmacology. The in-vitro concentrations at which ivermectin starts killing cancer cells run roughly 2.5 to 20 micromolar. The peak plasma concentration in a healthy human after the standard antiparasitic dose, around 200 micrograms per kilogram, is about 46 nanograms per milliliter, which works out to roughly 0.05 micromolar. The dish needs about fifty times what the bloodstream achieves to start working at the low end of that range, and nearly four hundred times at the top. You cannot wave that away with anecdote, and the reviewers do not try. They write that clinical validation remains limited and that rigorous trials are essential. What passes for human data, in their own catalogue, is an observational survey in rural Loja finding that 18.75 percent of cancer patients there were taking ivermectin as alternative therapy, and a thin scatter of case reports. That is not a clinical record. It is half a lab, a population sign, and a great many people self-prescribing on hope.

The honest analysis of why the question has been allowed to sit unanswered is the part the joke was designed to bury. Ivermectin is a forty-year-old generic. There is no patent left to defend, no exclusivity to monetize, no pipeline molecule whose revenue depends on the answer coming out one way or the other. The pharmaceutical industry is built around recouping nine-figure development costs from new chemical entities under exclusivity, and a seventy-cent off-patent compound is a strictly unprofitable hypothesis to chase. The same oncology research ecosystem that finds the budget for the eighty-third me-too checkpoint inhibitor cannot, somehow, find the budget for a Phase III trial on a generic. None of that proves the drug works in humans. It is the reason the question of whether it does has been allowed to drift, more than a decade after the first preclinical signals landed, with no one of consequence willing to settle it.

The COVID era then did the rest. A drug that had been a quiet curiosity in repurposing literature became, for reasons that had nothing to do with its oncology profile, a punchline. Whether the stigma actually made neutral inquiry on the molecule professionally costly inside oncology departments is interpretation, not citation. What is not interpretation is that the trial work the cancer question deserves still did not happen during those years.

Dispatching a real biological question by ridicule is rarely free, and this one has not been. It has produced a vacuum, and the vacuum has been filled, predictably, by people willing to sell the strong version of the story to a public that no longer trusts the institutions doing the dismissing. You can buy a protocol online from any number of repurposed-drug entrepreneurs. The gentlemanly objection (there is no good clinical evidence) and the populist objection (the institutions lied about everything else, why not this) have both been allowed to harden into permanent positions, with the trial work that would actually resolve them not happening. That is a failure of the system, not of either side of the argument.

Against that backdrop, what is happening in the world is a single Phase I/II study at Cedars-Sinai in Los Angeles, NCT05318469, led by breast-oncology director Yuan Yuan and pairing ivermectin with the checkpoint inhibitors balstilimab or pembrolizumab in thirty-four women with metastatic triple-negative breast cancer. The rationale is one of the more interesting threads in the preclinical literature. Ivermectin appears, in animal models, to flip immunologically cold tumors hot, recruiting T cells into a tumor microenvironment that had been ignoring them, and making immunotherapy work where it otherwise did not. The trial began in October 2023 and is scheduled to read out around late 2026. Thirty-four patients is not a definitive answer to anything. It is, however, the only trial of its kind, ivermectin paired with checkpoint blockade in a human cancer indication, that the public registry currently lists, and the size of that disproportion is the point.

A reader looking at this review for permission to add ivermectin to a cancer-treatment regimen on their own will not get it from the evidence. The pharmacology gap is too large, the case material too thin, the trials too few. A reader looking for vindication that the mockery of the last few years was scientifically justified will not get that either. The biology is too coherent and too reproducible to wave off. What the record actually shows is a drug with a forty-year safety profile, a consistent set of anticancer mechanisms in the dish and the mouse, almost no human evidence to speak of, and one small trial in Los Angeles because exactly one investigator was willing to ask the question seriously.

The horse-paste joke was doing two things at once. It was waving off a strong claim that the evidence did not support, and in the same motion it was waving off a weaker, more interesting claim that the evidence very much did. The weaker claim has been waiting more than a decade for somebody with funding to take it seriously. One Phase I/II study at one cancer center, run by one investigator, should not be the whole answer the oncology establishment has to a question this many people are asking.

Sources

  1. Robalino KN, Vivanco-Galván O, Romero-Benavides JC, Jiménez-Gaona Y. “Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential.” Pharmaceuticals (Basel) 2025;18(10):1459.
  2. Guzzo CA et al. “Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects.” J Clin Pharmacol 2002;42(10):1122-33.
  3. ClinicalTrials.gov NCT05318469 – Cedars-Sinai Phase I/II of ivermectin plus balstilimab or pembrolizumab in metastatic triple-negative breast cancer.
  4. TrialSite News, “Can Ivermectin Fight Cancer? New Review Finds Intriguing Biology – but Little Human Evidence,” 11 June 2026.
  5. PMC mirror of the Robalino et al. systematic review – full open-access text.